Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
News|Articles|August 3, 2026
FDA Action Update, July 2026: Approval, Acceptances, and Advisory Committee Vote
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology headlines you may have missed in July 2026, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in July 2026, making a number of decisions on potential new therapeutic agents, including a formulation approval, acceptances of new drug applications (NDAs), and voting at an advisory committee meeting.
Related to this article
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Seven experimental DM1 therapies show promise and pitfalls; see latest trial data, a major phase 3 miss, and key 2026 readouts.
The FDA has approved zilganersen (Zanvastro), the first Alexander disease treatment, giving clinicians a disease-modifying option and a clearer framework for counseling patients across the full age and phenotype spectrum.
Here's some of what is coming soon to NeurologyLive® this week.
FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
Advertisement
Advertisement